| [1] |
LU M, ZHOU YR, HALLER IV, et al. Increasing prevalence of primary biliary cholangitis and reduced mortality with treatment[J]. Clin Gastroenterol Hepatol, 2018, 16( 8): 1342- 1350. e 1. DOI: 10.1016/j.cgh.2017.12.033. |
| [2] |
ZENG N, DUAN WJ, CHEN S, et al. Epidemiology and clinical course of primary biliary cholangitis in the Asia-Pacific region: A systematic review and meta-analysis[J]. Hepatol Int, 2019, 13( 6): 788- 799. DOI: 10.1007/s12072-019-09984-x. |
| [3] |
TRIVELLA J, JOHN BV, LEVY C. Primary biliary cholangitis: Epidemiology, prognosis, and treatment[J]. Hepatol Commun, 2023, 7( 6): e0179. DOI: 10.1097/HC9.0000000000000179. |
| [4] |
TANAKA A, LEUNG PS, GERSHWIN ME. Environmental basis of primary biliary cholangitis[J]. Exp Biol Med(Maywood), 2018, 243( 2): 184- 189. DOI: 10.1177/1535370217748893. |
| [5] |
HOURI I, HIRSCHFIELD GM. Primary biliary cholangitis: Pathophysiology[J]. Clin Liver Dis, 2024, 28( 1): 79- 92. DOI: 10.1016/j.cld.2023.06.006. |
| [6] |
CHALIFOUX SL, KONYN PG, CHOI G, et al. Extrahepatic manifestations of primary biliary cholangitis[J]. Gut Liver, 2017, 11( 6): 771- 780. DOI: 10.5009/gnl16365. |
| [7] |
EFE C, TORGUTALP M, HENRIKSSON I, et al. Extrahepatic autoimmune diseases in primary biliary cholangitis: Prevalence and significance for clinical presentation and disease outcome[J]. J Gastroenterol Hepatol, 2021, 36( 4): 936- 942. DOI: 10.1111/jgh.15214. |
| [8] |
ROLL J, BOYER JL, BARRY D, et al. The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis[J]. N Engl J Med, 1983, 308( 1): 1- 7. DOI: 10.1056/NEJM198301063080101. |
| [9] |
DICKSON ER, GRAMBSCH PM, FLEMING TR, et al. Prognosis in primary biliary cirrhosis: Model for decision making[J]. Hepatology, 1989, 10( 1): 1- 7. DOI: 10.1002/hep.1840100102. |
| [10] |
KIM WR, WIESNER RH, POTERUCHA JJ, et al. Adaptation of the Mayo primary biliary cirrhosis natural history model for application in liver transplant candidates[J]. Liver Transpl, 2000, 6( 4): 489- 494. DOI: 10.1053/jlts.2000.6503. |
| [11] |
MIJIC M, SARIC I, DELIJA B, et al. Pretransplant evaluation and liver transplantation outcome in PBC patients[J]. Can J Gastroenterol Hepatol, 2022, 2022: 7831165. DOI: 10.1155/2022/7831165. |
| [12] |
GOET JC, MURILLO PEREZ CF, HARMS MH, et al. A comparison of prognostic scores(mayo, UK-PBC, and GLOBE) in primary biliary cholangitis[J]. Am J Gastroenterol, 2021, 116( 7): 1514- 1522. DOI: 10.14309/ajg.0000000000001285. |
| [13] |
FENG J, XU JM, FU HY, et al. Prognostic scores in primary biliary cholangitis patients with advanced disease[J]. World J Gastrointest Surg, 2023, 15( 8): 1774- 1783. DOI: 10.4240/wjgs.v15.i8.1774. |
| [14] |
CHRISTENSEN E, NEUBERGER J, CROWE J, et al. Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis. Final results of an international trial[J]. Gastroenterology, 1985, 89( 5): 1084- 1091. DOI: 10.1016/0016-5085(85)90213-6. |
| [15] |
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis[J]. J Hepatol, 2017, 67( 1): 145- 172. DOI: 10.1016/j.jhep.2017.03.022. |
| [16] |
ANGULO P, LINDOR KD, THERNEAU TM, et al. Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid[J]. Liver, 1999, 19( 2): 115- 121. DOI: 10.1111/j.1478-3231.1999.tb00020.x. |
| [17] |
PARÉS A, CABALLERÍA L, RODÉS J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid[J]. Gastroenterology, 2006, 130( 3): 715- 720. DOI: 10.1053/j.gastro.2005.12.029. |
| [18] |
CORPECHOT C, ABENAVOLI L, RABAHI N, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis[J]. Hepatology, 2008, 48( 3): 871- 877. DOI: 10.1002/hep.22428. |
| [19] |
LAMMERS WJ, van BUUREN HR, HIRSCHFIELD GM, et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: An international follow-up study[J]. Gastroenterology, 2014, 147( 6): 1338- 1349. e5; quize 15. DOI: 10.1053/j.gastro.2014.08.029. |
| [20] |
CARBONE M, SHARP SJ, FLACK S, et al. The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis[J]. Hepatology, 2016, 63( 3): 930- 950. DOI: 10.1002/hep.28017. |
| [21] |
KUIPER EMM, HANSEN BE, de VRIES RA, et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid[J]. Gastroenterology, 2009, 136( 4): 1281- 1287. DOI: 10.1053/j.gastro.2009.01.003. |
| [22] |
BALASUBRAMANIAM K, GRAMBSCH PM, WIESNER RH, et al. Diminished survival in asymptomatic primary biliary cirrhosis. A prospective study[J]. Gastroenterology, 1990, 98( 6): 1567- 1571. DOI: 10.1016/0016-5085(90)91091-J. |
| [23] |
AZEMOTO N, ABE M, MURATA Y, et al. Early biochemical response to ursodeoxycholic acid predicts symptom development in patients with asymptomatic primary biliary cirrhosis[J]. J Gastroenterol, 2009, 44( 6): 630- 634. DOI: 10.1007/s00535-009-0051-9. |
| [24] |
AZEMOTO N, KUMAGI T, ABE M, et al. Biochemical response to ursodeoxycholic acid predicts long-term outcome in Japanese patients with primary biliary cirrhosis[J]. Hepatol Res, 2011, 41( 4): 310- 317. DOI: 10.1111/j.1872-034X.2011.00782.x. |
| [25] |
KUMAGI T, GUINDI M, FISCHER SE, et al. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis[J]. Am J Gastroenterol, 2010, 105( 10): 2186- 2194. DOI: 10.1038/ajg.2010.216. |
| [26] |
ZHANG LN, SHI TY, SHI XH, et al. Early biochemical response to ursodeoxycholic acid and long-term prognosis of primary biliary cirrhosis: Results of a 14-year cohort study[J]. Hepatology, 2013, 58( 1): 264- 272. DOI: 10.1002/hep.26322. |
| [27] |
TABABI R, MRABET S, AKKARI I, et al. Prognostic scores in primary biliary cholangitis[J]. Future Sci OA, 2024, 10( 1): FSO975. DOI: 10.2144/fsoa-2023-0203. |
| [28] |
TRIVEDI PJ, BRUNS T, CHEUNG A, et al. Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response[J]. J Hepatol, 2014, 60( 6): 1249- 1258. DOI: 10.1016/j.jhep.2014.01.029. |
| [29] |
JOHNSON PJ, BERHANE S, KAGEBAYASHI C, et al. Assessment of liver function in patients with hepatocellular carcinoma: A new evidence-based approach-the ALBI grade[J]. J Clin Oncol, 2015, 33( 6): 550- 558. DOI: 10.1200/JCO.2014.57.9151. |
| [30] |
CHAN AWH, CHAN RCK, WONG GLH, et al. New simple prognostic score for primary biliary cirrhosis: Albumin-bilirubin score[J]. J Gastroenterol Hepatol, 2015, 30( 9): 1391- 1396. DOI: 10.1111/jgh.12938. |
| [31] |
CHEN QL, ZHONG R, WANG Y, et al. The albumin-bilirubin score as a predictor of liver-related mortality in primary biliary cholangitis with compensated cirrhosis[J]. Dig Dis, 2023, 41( 6): 946- 956. DOI: 10.1159/000531557. |
| [32] |
ITO T, ISHIGAMI M, MOROOKA H, et al. The albumin-bilirubin score as a predictor of outcomes in Japanese patients with PBC: An analysis using time-dependent ROC[J]. Sci Rep, 2020, 10( 1): 17812. DOI: 10.1038/s41598-020-74732-3. |
| [33] |
LAMMERS WJ, HIRSCHFIELD GM, CORPECHOT C, et al. Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy[J]. Gastroenterology, 2015, 149( 7): 1804- 1812. e 4. DOI: 10.1053/j.gastro.2015.07.061. |
| [34] |
CARBONE M, HARMS MH, LAMMERS WJ, et al. Clinical application of the GLOBE and United Kingdom-primary biliary cholangitis risk scores in a trial cohort of patients with primary biliary cholangitis[J]. Hepatol Commun, 2018, 2( 6): 683- 692. DOI: 10.1002/hep4.1180. |
| [35] |
SOHAL A, KOWDLEY KV. Primary biliary cholangitis: Promising emerging innovative therapies and their impact on GLOBE scores[J]. Hepat Med, 2023, 15: 63- 77. DOI: 10.2147/HMER.S361077. |
| [36] |
CHEUNG AC, GULAMHUSEIN AF, JURAN BD, et al. External validation of the United Kingdom-primary biliary cholangitis risk scores of patients with primary biliary cholangitis treated with ursodeoxycholic acid[J]. Hepatol Commun, 2018, 2( 6): 676- 682. DOI: 10.1002/hep4.1186. |
| [37] |
YANG F, YANG Y, WANG Q, et al. The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: The additional effect of anti-gp210[J]. Aliment Pharmacol Ther, 2017, 45( 5): 733- 743. DOI: 10.1111/apt.13927. |
| [38] |
ALOMARI M, COVUT F, MOMANI L AL, et al. Evaluation of the United Kingdom-primary biliary cholangitis and global primary biliary cholangitis group prognostic models for primary biliary cholangitis patients treated with ursodeoxycholic acid in the U.S. population[J]. JGH Open, 2020, 4( 2): 132- 139. DOI: 10.1002/jgh3.12223. |
| [39] |
CHEUNG KS, SETO WK, FUNG J, et al. Prognostic factors for transplant-free survival and validation of prognostic models in Chinese patients with primary biliary cholangitis receiving ursodeoxycholic acid[J]. Clin Transl Gastroenterol, 2017, 8( 6): e100. DOI: 10.1038/ctg.2017.23. |
| [40] |
MARENCO-FLORES A, ROJAS AMARIS N, KAHAN T, et al. The external validation of GLOBE and UK-PBC risk scores for predicting ursodeoxycholic acid treatment response in a large U.S. cohort of primary biliary cholangitis patients[J]. J Clin Med, 2024, 13( 15): 4497. DOI: 10.3390/jcm13154497. |
| [41] |
WANG R, MA JL, ZHANG FK, et al. Prediction of decompensation in patients with primary biliary cirrhosis[J]. Chin Hepatol, 2012, 17( 7): 460- 464.
王蕊, 马佳丽, 张福奎, 等. 原发性胆汁性肝硬化发生失代偿的预测[J]. 肝脏, 2012, 17( 7): 460- 464.
|
DownLoad: